India orders Sun Pharma to halt eye-care drug production at plant after quality lapses

In recent months, Indian drug regulators have faced intense pressure to tighten quality controls after locally produced cough syrups were connected to the deaths of children both within the country and abroad, including in Gambia and Uzbekistan. The incidents sparked a nationwide debate about manufacturing practices, prompting the Ministry of Health and Family Welfare to launch a series of inspections across major pharmaceutical facilities. Sun Pharma, one of the country's largest drug exporters, was found to have shortcomings in its eye‑care product line during a routine audit.

The specific plant ordered to halt production was cited for deviations from established Good Manufacturing Practices, including inadequate sterility testing and incomplete documentation of batch records. The regulator demanded that Sun Pharma conduct a full root‑cause analysis, remediate the identified gaps, and submit a corrective action plan before any further manufacturing could resume. The suspension affects the supply of the eye‑care medication, which is used to treat conditions such as dry eye syndrome and postoperative inflammation, potentially creating short‑term shortages for patients who rely on the product.

For Indian consumers, the episode underscores the importance of stringent oversight in a sector that supplies both domestic patients and international markets. It also highlights the government's resolve to protect public health by enforcing compliance, even when it involves major industry players. Patients currently using the affected medication should consult their ophthalmologists for alternative treatments, while industry observers will be tracking how quickly Sun Pharma can address the deficiencies and restart production.